Selective COX-II Inhibitor as an Adjuvant Therapy in Patients With Resectable Advanced Stomach Cancer ( Histological Staging ≥ T2N1) - A Multi-Centre Prospective Randomised Controlled Trial

NCT00164892 Phase 3 UNKNOWN

The purpose of this study is to investigate the efficacy of selective COX-II inhibitor in patients with curative resection performed for locally advanced stomach cancer.

Details

Lead sponsor	Chinese University of Hong Kong
Phase	Phase 3
Status	UNKNOWN
Enrolment	214
Start date	2004-10

Conditions

• Cancer of Stomach

Interventions

• Oral Vioxx (Rofecoxib)

Primary outcomes

• Recurrence free survival and the quality of life score within the two years of study period

Countries

China